Graduate School of Biomedical Sciences

Medicine & Life Sciences

1. Neoplasms 100%
2. MicroRNAs 96%
3. Breast Neoplasms 68%
4. Survival 39%
5. Genes 38%
6. Ovarian Neoplasms 32%
7. Radiotherapy 31%
8. Therapeutics 30%
9. Esophageal Neoplasms 27%
10. Recurrence 26%
11. Growth 25%
12. Catenins 25%
13. Non-Small Cell Lung Carcinoma 24%
14. Radiation 24%
15. Untranslated RNA 24%
16. Neoplasm Metastasis 24%
17. Drug Therapy 24%
18. Leukemia 21%
19. Proteins 21%
20. Melanoma 21%
21. Acute Myeloid Leukemia 21%
22. Long Noncoding RNA 20%
23. T-Lymphocytes 20%
24. Mutation 19%
25. Breast 18%
26. Cell Line 18%
27. Adenocarcinoma 17%
28. Apoptosis 17%
29. Carcinoma 16%
30. Sarcoma 16%
31. Gene Expression 16%
32. Carcinogenesis 15%
33. Glioblastoma 15%
34. Proton Therapy 14%
35. Biomarkers 14%
36. B-Cell Chronic Lymphocytic Leukemia 13%
37. DNA 13%
38. Single Nucleotide Polymorphism 13%
39. Ovarian Epithelial Carcinoma 13%
40. Precursor Cell Lymphoblastic Leukemia-Lymphoma 13%
41. Chemoradiotherapy 13%
42. In Vitro Techniques 13%
43. RNA 13%
44. Bone Marrow 12%
45. Colorectal Neoplasms 12%
46. Lung Neoplasms 12%
47. Sentinel Lymph Node 12%
48. Cell Proliferation 12%
49. Glioma 11%
50. delta catenin 11%
51. Phenotype 11%
52. Confidence Intervals 10%
53. Tumor Suppressor Genes 10%
54. Chromatin 10%
55. Stem Cells 10%
56. Integrins 9%
57. Transcription Factors 9%
58. Epigenomics 9%
59. Carcinoma, Intraductal, Noninfiltrating 9%
60. Down-Regulation 9%
61. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9%
62. Messenger RNA 9%
63. Methylation 9%
64. Triple Negative Breast Neoplasms 9%
65. Segmental Mastectomy 9%
66. Interleukin-1 8%
67. Genome 8%
68. Lymph Nodes 8%
69. Immunotherapy 8%
70. Lung 8%
71. Myelodysplastic Syndromes 8%
72. Lymphocytes 8%
73. Epithelial Cells 8%
74. Estrogen Receptors 8%
75. Liver 8%
76. Neoplastic Stem Cells 8%
77. Liposarcoma 8%
78. Chromosomes 8%
79. Inflammatory Breast Neoplasms 8%
80. Photons 7%
81. Cadherins 7%
82. Cytogenetics 7%
83. Tumor Microenvironment 7%
84. Phosphotransferases 7%
85. Mastectomy 7%
86. Cytokines 7%
87. Loss of Heterozygosity 7%
88. DNA Damage 7%
89. Protons 7%
90. ErbB Receptors 7%
91. Epithelial-Mesenchymal Transition 7%
92. TOR Serine-Threonine Kinases 7%
93. Renal Cell Carcinoma 7%
94. Skin 7%
95. Trastuzumab 7%
96. Genetic Variation 7%
97. Macrophages 7%
98. Phosphatidylinositol 3-Kinase 6%
99. Lymphopenia 6%
100. Prostatic Neoplasms 6%